Weijun Wei, Di Zhang, You Zhang, Lianghua Li, Yuchen Jin, Shuxian An, Chun Lv, Haitao Zhao, Cheng Wang, Yanshan Huang, Jiali Dong, Gang Huang, Jianjun Liu
{"title":"探测claud18.2的68Ga/18F/ 64cu标记纳米体示踪剂的研制与比较","authors":"Weijun Wei, Di Zhang, You Zhang, Lianghua Li, Yuchen Jin, Shuxian An, Chun Lv, Haitao Zhao, Cheng Wang, Yanshan Huang, Jiali Dong, Gang Huang, Jianjun Liu","doi":"10.1016/j.omto.2022.11.003","DOIUrl":null,"url":null,"abstract":"<p><p>Claudin 18.2 (CLDN18.2) is an emerging target for the treatment of gastric cancers. We aim to develop tracers to image the expression of CLDN18.2. A humanized nanobody targeting CLDN18.2 (clone hu19V3) was produced and labeled with <sup>68</sup>Ga, <sup>64</sup>Cu, and <sup>18</sup>F. The tracers were investigated in subcutaneous and metastatic models established using two different mouse types (nude and Balb/c mice) and two different cell lines (CHO-CLDN18.2 and CT26-CLDN18.2). Gastric cancer patient-derived xenograft (PDX) models were further established for validation experiments. Three novel CLDN18.2-targeted tracers (i.e., [<sup>68</sup>Ga]Ga-NOTA-hu19V3, [<sup>64</sup>Cu]Cu-NOTA-hu19V3, and [<sup>18</sup>F]F-hu19V3) were developed with good radiochemical yields and excellent radiochemical purities. [<sup>68</sup>Ga]Ga-NOTA-hu19V3 immuno-positron emission tomography (immunoPET) rapidly delineated subcutaneous CHO-CLDN18.2 lesions and CT26-CLDN18.2 tumors, as well as showing excellent diagnostic value in PDX models naturally expressing CLDN18.2. While [<sup>68</sup>Ga]Ga-NOTA-hu19V3 had high kidney accumulation, [<sup>64</sup>Cu]Cu-NOTA-hu19V3 showed reduced kidney accumulation and improved image contrast at late time points. Moreover, [<sup>18</sup>F]F-hu19V3 was developed via click chemistry reaction under mild conditions and precisely disseminated CHO-CLDN18.2 lesions in the lungs. Furthermore, region of interest analysis, biodistribution study, and histopathological staining results correlated well with the <i>in vivo</i> imaging results. Taken together, immunoPET imaging with the three tracers can reliably visualize CLDN18.2 expression.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/51/main.PMC9747674.pdf","citationCount":"5","resultStr":"{\"title\":\"Development and comparison of <sup>68</sup>Ga/<sup>18</sup>F/<sup>64</sup>Cu-labeled nanobody tracers probing Claudin18.2.\",\"authors\":\"Weijun Wei, Di Zhang, You Zhang, Lianghua Li, Yuchen Jin, Shuxian An, Chun Lv, Haitao Zhao, Cheng Wang, Yanshan Huang, Jiali Dong, Gang Huang, Jianjun Liu\",\"doi\":\"10.1016/j.omto.2022.11.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Claudin 18.2 (CLDN18.2) is an emerging target for the treatment of gastric cancers. We aim to develop tracers to image the expression of CLDN18.2. A humanized nanobody targeting CLDN18.2 (clone hu19V3) was produced and labeled with <sup>68</sup>Ga, <sup>64</sup>Cu, and <sup>18</sup>F. The tracers were investigated in subcutaneous and metastatic models established using two different mouse types (nude and Balb/c mice) and two different cell lines (CHO-CLDN18.2 and CT26-CLDN18.2). Gastric cancer patient-derived xenograft (PDX) models were further established for validation experiments. Three novel CLDN18.2-targeted tracers (i.e., [<sup>68</sup>Ga]Ga-NOTA-hu19V3, [<sup>64</sup>Cu]Cu-NOTA-hu19V3, and [<sup>18</sup>F]F-hu19V3) were developed with good radiochemical yields and excellent radiochemical purities. [<sup>68</sup>Ga]Ga-NOTA-hu19V3 immuno-positron emission tomography (immunoPET) rapidly delineated subcutaneous CHO-CLDN18.2 lesions and CT26-CLDN18.2 tumors, as well as showing excellent diagnostic value in PDX models naturally expressing CLDN18.2. While [<sup>68</sup>Ga]Ga-NOTA-hu19V3 had high kidney accumulation, [<sup>64</sup>Cu]Cu-NOTA-hu19V3 showed reduced kidney accumulation and improved image contrast at late time points. Moreover, [<sup>18</sup>F]F-hu19V3 was developed via click chemistry reaction under mild conditions and precisely disseminated CHO-CLDN18.2 lesions in the lungs. Furthermore, region of interest analysis, biodistribution study, and histopathological staining results correlated well with the <i>in vivo</i> imaging results. Taken together, immunoPET imaging with the three tracers can reliably visualize CLDN18.2 expression.</p>\",\"PeriodicalId\":18869,\"journal\":{\"name\":\"Molecular Therapy Oncolytics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2022-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/51/main.PMC9747674.pdf\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Therapy Oncolytics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.omto.2022.11.003\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy Oncolytics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omto.2022.11.003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2.
Claudin 18.2 (CLDN18.2) is an emerging target for the treatment of gastric cancers. We aim to develop tracers to image the expression of CLDN18.2. A humanized nanobody targeting CLDN18.2 (clone hu19V3) was produced and labeled with 68Ga, 64Cu, and 18F. The tracers were investigated in subcutaneous and metastatic models established using two different mouse types (nude and Balb/c mice) and two different cell lines (CHO-CLDN18.2 and CT26-CLDN18.2). Gastric cancer patient-derived xenograft (PDX) models were further established for validation experiments. Three novel CLDN18.2-targeted tracers (i.e., [68Ga]Ga-NOTA-hu19V3, [64Cu]Cu-NOTA-hu19V3, and [18F]F-hu19V3) were developed with good radiochemical yields and excellent radiochemical purities. [68Ga]Ga-NOTA-hu19V3 immuno-positron emission tomography (immunoPET) rapidly delineated subcutaneous CHO-CLDN18.2 lesions and CT26-CLDN18.2 tumors, as well as showing excellent diagnostic value in PDX models naturally expressing CLDN18.2. While [68Ga]Ga-NOTA-hu19V3 had high kidney accumulation, [64Cu]Cu-NOTA-hu19V3 showed reduced kidney accumulation and improved image contrast at late time points. Moreover, [18F]F-hu19V3 was developed via click chemistry reaction under mild conditions and precisely disseminated CHO-CLDN18.2 lesions in the lungs. Furthermore, region of interest analysis, biodistribution study, and histopathological staining results correlated well with the in vivo imaging results. Taken together, immunoPET imaging with the three tracers can reliably visualize CLDN18.2 expression.
期刊介绍：
Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
